Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
236 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (3)
  • Currently Recruiting (1)
  • (-) Closed (2)

Medical Condition

  • Show all (1001)
  • Addiction (14)
    • (-) Alcohol (1)
    • Cocaine (2)
    • Marijuana (2)
    • Nicotine (2)
    • Opioids (6)
  • Allergy, Asthma, & Immunology (11)
    • (-) Allergy (1)
    • Asthma (7)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (25)
  • Blood Disorders (18)
  • Bone & Muscle (8)
  • Cancer (90)
  • Child Development (4)
  • COVID-19 (Coronavirus) (28)
  • Critical Illness (1)
  • Diabetes (13)
  • Ear, Nose and Throat (5)
  • Endocrine & Metabolic Disease (11)
  • Eye (7)
  • Gastrointestinal and Digestive Diseases (23)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (142)
  • Heart Disease (111)
  • Infectious Disease (40)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (43)
  • Lung Disease (29)
  • Meniere's Disease (1)
  • Neurological Disorders (96)
  • Nutrition (3)
  • Obesity (2)
  • Obstetrics & Gynecology (46)
  • Pain Management (1)
  • Pediatrics (83)
  • Psychiatric Disorders (60)
  • Rehabilitation (7)
  • Stroke (5)
  • Surgery (7)
  • Transplant (33)
  • Urology (3)
  • Vascular Conditions (9)
Displaying 1 - 2 of 2

Study of Remibrutinib (LOU064) in Patients with Peanut Allergy

Condition: Allergy, Asthma, & Immunology / Allergy
Investigator: Joyce Yu, MD
Status: Closed
The study population includes up to 110 adult male and female participants ages 18-55 years. Participants may have multiple food allergies but must be peanut allergic in order to be included. Safety assessments will include the following: physical examination, vital signs, laboratory evaluations, and ECG (electrocardiogram).
Read More

Study to Evaluate the Efficacy & Safety of Treatment with Efimosfermin Alfa in Adult Participants with Alcohol-related Liver Disease (ALD)

Condition: Addiction / Alcohol
Investigator: Gene Im, MD, FAASLD
Status: Closed
Researchers at Columbia University Irving Medical Center are investigating whether the investigational medication efimosfermin is safe and effective in improving outcomes for adults with Alcohol-related Liver Disease (ALD). ALD refers to liver damage caused by heavy alcohol consumption. The study uses a placebo for comparison because there are no approved…
Read More
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Terms of Use Privacy Policy ©2026 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science